PRISM evaluates 4D-150, a potential backbone therapy designed to provide multi-year sustained delivery of anti-VEGF ...

Loss to follow-up higher among men who are Black or Hispanic, or those who must travel farther to care facilities.

D Molecular Therapeutics reported 52-week Phase 2b data for 4D-150 in wet AMD, showing sustained visual acuity improvements.

A new review reports that nine people taking semaglutide and tirzepatide — the active ingredient in GLP-1 medications — experienced vision issues, including three potentially blinding eye conditions.

Older women could be vulnerable to harmful inflammation from new gene therapies to treat incurable eye diseases, new research has found.

MONDAY, Feb. 10, 2025 (HealthDay News) -- Yes, rare cases of vision issues have arisen in people taking popular GLP-1 weight ...

Google and Perceptra, a Google technology licensing partner, are joining forces to provide AI-powered diabetic-retinopathy (DR) screening to around 1 million people in underserved communities across ...

A new study from Mass Eye and Ear suggests that people taking semaglutide, a drug sold as Ozempic and Wegovy, may have a ...

Diabetes, which affects 4% of adults globally, can cause severe complications such as kidney disease and nerve damage.

The FDA has approved Susvimo (ranibizumab injection) for the treatment of patients with diabetic macular edema.

Objectives This study aims to study the association between socioeconomic factors and risk of prevalent eye diseases, ...

The U.S. Food and Drug Administration has approved Susvimo (ranibizumab) 100 mg/mL for treating diabetic macular edema.